Bilateral refractory pneumothorax treated by pleurodesis and bronchial occlusion in a COVID‐19 patient

Coronavirus disease 2019 (COVID‐19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID‐19 is relatively uncommon. We herein report a 60‐year‐old man with bilateral refractory pneumothorax with severe COVID‐19. In patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Satoshi, Takayama, Yoshihiro, Kitou, Riiko, Asakawa, Ryo, Tobita, Satoshi, Ike, Akihiro, Kawada, Masahiro, Yamamoto, Suguru, Ueno, Kiyonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771784/
https://www.ncbi.nlm.nih.gov/pubmed/36567689
http://dx.doi.org/10.1002/ccr3.6754
Descripción
Sumario:Coronavirus disease 2019 (COVID‐19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID‐19 is relatively uncommon. We herein report a 60‐year‐old man with bilateral refractory pneumothorax with severe COVID‐19. In patients with poor general health and who are difficult to undergo surgery for pneumothorax post‐COVID‐19, internal treatments such as chest drainage, bronchial occlusion, and pleurodesis are essential to relieving refractory pneumothorax. It also indicates that autologous blood patch pleurodesis is a useful method in terms of efficacy and side effects.

Ejemplares similares